Ülke: Kanada
Dil: İngilizce
Kaynak: Health Canada
ANIDULAFUNGIN
GENMED A DIVISION OF PFIZER CANADA ULC
J02AX06
ANIDULAFUNGIN
100MG
POWDER FOR SOLUTION
ANIDULAFUNGIN 100MG
INTRAVENOUS
100
Prescription
ECHINOCANDINS
Active ingredient group (AIG) number: 0152373001; AHFS:
CANCELLED PRE MARKET
2021-01-15
_ _ _GD-Anidulafungin (anidulafungin) - Product Monograph _ _Page 1 of 28_ PRODUCT MONOGRAPH PR GD*-ANIDULAFUNGIN Anidulafungin For Injection 100 mg / Vial ANTIFUNGAL AGENT GenMed, a Division of Pfizer Canada Inc. 17 300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Date of Preparation: May 26, 2015 Submission Control No: 183521 * GD is a trademark of Pfizer Canada Inc. GenMed, a division of Pfizer Canada Inc., Licensee © Pfizer Canada Inc., 2015 _ _ _GD-Anidulafungin (anidulafungin) - Product Monograph _ _Page 2 of 28_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ........................................................................ 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 3 WARNINGS AND PRECAUTIONS ................................................................................. 3 ADVERSE REACTIONS ................................................................................................... 4 DRUG INTERACTIONS ................................................................................................... 9 DOSAGE AND ADMINISTRATION ............................................................................. 11 OVERDOSAGE ................................................................................................................ 12 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 13 STORAGE AND STABILITY ......................................................................................... 16 SPECIAL HANDLING INSTRUCTIONS ....................................................................... 16 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................. 16 PART II: SCIENTIFIC INFORMATION ................................................... Belgenin tamamını okuyun